These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 8899248

  • 1. Memory impairment in schizophrenia: perspectives from psychopathology and pharmacotherapy.
    Stip E.
    Can J Psychiatry; 1996 Oct; 41(8 Suppl 2):S27-34. PubMed ID: 8899248
    [Abstract] [Full Text] [Related]

  • 2. Donepezil for memory dysfunction in schizophrenia.
    Howard AK, Thornton AE, Altman S, Honer WG.
    J Psychopharmacol; 2002 Sep; 16(3):267-70. PubMed ID: 12236636
    [Abstract] [Full Text] [Related]

  • 3. Discriminant cognitive factors in responder and non-responder patients with schizophrenia.
    Stip E, Lussier I, Ngan E, Mendrek A, Liddle P.
    Eur Psychiatry; 1999 Dec; 14(8):442-50. PubMed ID: 10683630
    [Abstract] [Full Text] [Related]

  • 4. Two new atypical antipsychotics: advantages and disadvantages.
    Lemon MD.
    S D J Med; 1998 Aug; 51(8):285-6. PubMed ID: 9724957
    [No Abstract] [Full Text] [Related]

  • 5. The effect of risperidone on cognition in patients with schizophrenia.
    Stip E, Lussier I.
    Can J Psychiatry; 1996 Oct; 41(8 Suppl 2):S35-40. PubMed ID: 8899249
    [Abstract] [Full Text] [Related]

  • 6. The value of atypical antipsychotics in the treatment of schizophrenia.
    Jessen LM.
    Manag Care; 2002 Jul; 11(7 Suppl):8-12; discussion 12-3. PubMed ID: 12181875
    [No Abstract] [Full Text] [Related]

  • 7. [Effect of side-effects and complications caused by atypical neuroleptics on the effectiveness of therapy in patients with schizophrenia].
    Danilov DS.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010 Jul; 110(3):48-55. PubMed ID: 20517226
    [Abstract] [Full Text] [Related]

  • 8. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
    Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R.
    Am J Psychiatry; 2002 Apr; 159(4):561-6. PubMed ID: 11925293
    [Abstract] [Full Text] [Related]

  • 9. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998 Apr; 59 Suppl 12():3-9. PubMed ID: 9766613
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M, Pecenak J, Szulc A, Irimia V, Anders M, Logozar-Perkovic D, Peciukaitiene D, Kotler M, Smulevich AB, West TM, Lowry AJ, Treuer T.
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [Abstract] [Full Text] [Related]

  • 12. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998 Dec; 59 Suppl 12():35-40. PubMed ID: 9766618
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The new antipsychotic compounds: is a clinical choice algorithm possible?
    Wirshing WC.
    West J Med; 1998 Jul; 169(1):43-4. PubMed ID: 9682633
    [No Abstract] [Full Text] [Related]

  • 16. A model of anticholinergic activity of atypical antipsychotic medications.
    Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Kirshner MA, Bies RR, Kapur S, Gharabawi G.
    Schizophr Res; 2006 Dec; 88(1-3):63-72. PubMed ID: 16928430
    [Abstract] [Full Text] [Related]

  • 17. Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone.
    Westheide J, Cvetanovska G, Albrecht C, Bliesener N, Cooper-Mahkorn D, Creutz C, Hornung WP, Klingmüller D, Lemke MR, Maier W, Schubert M, Sträter B, Kühn KU.
    J Sex Med; 2008 Dec; 5(12):2816-26. PubMed ID: 18466271
    [Abstract] [Full Text] [Related]

  • 18. Spontaneous and drug-induced movement disorders in schizophrenia.
    Kopala LC.
    Acta Psychiatr Scand Suppl; 1996 Dec; 389():12-7. PubMed ID: 8985472
    [Abstract] [Full Text] [Related]

  • 19. Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone.
    Tracy JI, Monaco CA, Abraham G, Josiassen RC, Pollock BG.
    J Clin Psychiatry; 1998 Apr; 59(4):184-8. PubMed ID: 9590669
    [Abstract] [Full Text] [Related]

  • 20. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.
    Ollendorf DA, Joyce AT, Rucker M.
    MedGenMed; 2004 Jan 20; 6(1):5. PubMed ID: 15208518
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.